aducanumab
eisai,biogen
['aducanumab', 'thanks']
in a session on accelerated approval, highlights the real impact on people of approving marginal/ineffective and highly expensive drugs.
the largest premium increase in many years, thanks to one drug: aducanumab #asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem